Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/12913
標題: 基質金屬蛋白酵素2及9在罹患淋巴瘤犬隻血清中的濃度改變
Altered levels of serum matrix metalloproteinase 2 and 9 in lymphoma-affected dogs
作者: 許如瑩
Hsu, Ju-Ying
關鍵字: matrix metalloproteinase
基質金屬蛋白酵素
lymphoma
淋巴瘤
出版社: 獸醫學系暨研究所
引用: Abbo AH, Lucroy MD, 2007. Assessment of anemia as an independent predictor ofresponse to chemotherapy and survival in dogs with lymphoma, 96 cases (1993-2006). Journal of American Veterinary Medicine Association 231, 1836-1842. Aresu L, Aricò A, Comazzi S, Gelain ME, Riondato F, Mortarino M, Morello E, Stefanello D, Castagnaro M, 2012. VEGF and MMP-9: biomarkers for canine lymphoma. Veterinary and Comparative Oncology 10. Beaver LM, Strottner G, Klein MK, 2010. Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008). Journal of American Veterinary Medicine Association 237, 1052-1055. Bergman RL, Inzana KD, Inzana TJ, 2002. Characterization of matrix metalloproteinase-2 and -9 in cerebrospinal fluid of clinically normal dogs. American Journal of Veterinary Research 63, 1359-1362. Bhang DH, Choi US, Kim MK, Choi EH, kang MS, Hwang CY, Kim DY, Youn HY, Lee CW, 2006. Epitheliotropic cutaneous lymphoma (mycosis fungoides) in a dog. Journal of Veterinary Science 7, 97-99. Carter RF, Valli VE, Lumsden JH, 1986. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Canadian Journal of Veterinary Reaserch 50, 154-164. Castellazzi M, Tamborino C, Fainardi E, Manfrinato MC, Granieri E, Dallocchio F, Bellini T, 2007. Effects of anticoagulants on the activity of gelatinases Clinical Biochemistry 40, 1272-1276. Chun R, 2009. Lymphoma: which chemotherapy protocol and why? Top Companion Animal Medicne 24, 157-162. Daniele A, Zito AF, Giannelli G, Divella R, Asselti M, Mazzocca A, Paradiso A, Quaranta M, 2010. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Reserch 30, 3521-3527. de Arespacochaga AG, Schwendenwein I, Weissenböck H, 2007. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. Journal of Comparative Pathology 136, 186-192. Dobson J, 2004. Classification of canine lymphoma: a step forward. The Veterinary Journal 167, 125-126. Dobson JM, Blackwood LB, Mc Innes EF, Bostock DE, Nicholls P, Hoather TM, Tom BD, 2001. Prognostic variables in canine multicentric lymphosarcoma. Journal of Small Animal Practice 42, 377-384. Egeblad, M. Werb, Z, 2002. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2, 161-174. Flory AB, Rassnick KM, Erb HN, Garrett LD, Northrup NC, Selting KA, Phillips BS, Locke JE, Chretin JD, 2011. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007). Journal of the American Veterinary Medical Association 238, 501-506. Fontaine J, Bovens C, Bettenay S, Mueller RS, 2009. Canine cutaneous epitheliotropic T-cell lymphoma: a review. Veterinary and Comparative Oncology 7, 1-14. Fontaine J, Heimann M, Day MJ, 2010. Canine cutaneous epitheliotropic T-cell lymphoma: a review of 30 cases. Veterinary Dermatology 21, 267-275. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM, 2002. Evaluation of a 6- month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 16, 704-709. Gavazza A, Lubas G, Valori E, Gugliucci B, 2008. Retrospective survey of malignant lymphoma cases in the dog: clinical, therapeutical and prognostic features. Veterinary Research Communication 32, s291-s293. Gavazza A, Presciuttini S, Barale R, Lubas G, Gugliucci B, 2001. Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. Journal of Veterinary Internal Medicine 15, 190-195. Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M, Bergamini PF, 2005. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma affected dogs. Leukemia Research 29, 1263-1269. Gerlach RF, Demacq C, Jung K, Tanus-Santos JE, 2007. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clinical Biochemistry 40, 119-123. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE, 2005. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities Analytical Biochemistry 344, 147-149. Hazar B, Polat G, Seyrek E, Bagdatoglglu O, Kanik A, Tiftik N, 2004. Prognostic value of matrix metalloproteinases (MMP-2 and MMP- 9) in Hodgkin's and non-Hodgkin's lymphoma. International Journal of Clinical Practice 58, 139-43. Herold M, Schulze A, Niederweiser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Muller C, Muller Chr, 2006. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin''s lymphoma and mantle lymphoma: Results of a randomized phase III trial (OSHO #19). Journal of Cancer Research Clinical Oncology 132, 105-112. Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S, 2002. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). Journal of Veterinary Medicine A 49, 419-424. Jung K, Lein M, Roemer A, Lichtihghagen R, 2002. Circulating gelatinase B (MMP-9)—the impact of preanalytical step in blood collection. Matrix Biology 21, 381-2. Keller ET, McEwen EG, Rosenthal RC, Helfand SC, Fox LE, 1993. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 7, 289-295. Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T, 2003. Gelatinases (MMP-2, MMP-9), TIMP-1 expression and extent of neovascularization in aggressive non-Hodgkin's lymphomas. European Journal of Haematology 71, 91-99. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T, 2002. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. European Journal of Haematology 69, 205-215. Kuittinen O, Savolainen ER, Koistinen P, Mottonen M, Turpeenniemi-Hujanen T, 2001. MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL) Leukemia Research 25, 125-131. Lalancette M, Aoudjit F, Potworowski EF, St-Pierre Y, 2000. Resistance of ICAM-1 deficient mice to metastasis overcome by increases aggressiveness of lymphoma cells. Blood 95, 314-319. Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, Huang KH, Lo CH, Hwang TL, 2008. Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histology and Histopathology 23, 515-521. Leibman NF, Lana SE, Hansen RA, Leibman NF, Lana SE, Hansen RA, 2000. Identification of matrix metalloproteinases in canine cutaneous mast cell tumors. Journal of Veterinary Internal Medicine 14, 583-586. Lowe A, 2004. Alimentary lymphosarcoma in a 4-year-old Labrador retriever. Canadian Veterinary Journal 45, 610-612. Lucas P, Lacoste H, de Lorimier LP, Fan TM, 2007. Treating paraneoplastic hypercalcemia in dogs and cats. Veterinary Medicine 102, 314-331. MacEven EG, Hayes AA, Matus RE, Kurzman I, 1987. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981). Journal of American Veterinary Medicine Association 190, 564-568. Miller AG, Morley PS, Rao S, Avery AC, Lana SE, Olver CS, 2009. Anemia is associated with decreased survival time in dogs with lymphoma. Journal of Veterinary Internal Medicine 23, 116-122. Morrison WB, 2005. Lymphoma in dogs and cats, 1st ed. Teton NewMedia, Jackson WY, USA, p. 3-5. Mutsaers AJ, Glickman NW, DeNicola DB, Widmer WR, Bonney PL, Hahn KA, Knapp DW, 2002. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. Journal of American Veterinary Medicine Association 220, 1813-1817. Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO, 2009. Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. Leukemia and Lymphoma 50, 998-1004. Newmana RG, Kitchell BE, Wallig MA, Paria B, 2008. The cloning and expression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase 2 in normal canine lymph nodes and in canine lymphoma. Research in Veterinary Science 84, 206-214. Nguyen M, Arkell J, Jackson CJ, 2001. Human endothelial gelatinases and angiogenesis. The International Journal of Biochemistry and Cell Biology 33, 960-970. Owen LN, 1980. WHO. In: Owen LN (Ed.), TNM Classification of Tumors in Domestic Animals. World Health Organization, Geneva, Switzerland, p. 47. Parodi AL, 2001. Classification of Malignant Lymphoma in Domestic Animals: History and Conceptual Evolution. European Journal of Veterinary Pathology 7, 43-50. Pastor M, Chalvet-Monfray K, Marchal T, Keck G, Magnol JP, Fournel-Fleury C, Ponce F, 2009. Genetic and invironmental risk indicators in canine non- Hodgkin's lymphomas: breeds associations and geographic distribution of 608 cases diagnosed through France over 1 year. Journal of veterinary Internal Medicine 23, 301-310. Pennanen H, Kuittinen O, Turpeenniemi-Hujanen T, 2007. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma. European Journal of Haematology 8, 46-54. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C, 2004. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Veterinary Journal 167, 158-166. Ponce F, Marchal T, Magnol JP, Turinelli V, Ledeu D, Bonnefont C, Pastor M, Delignette ML, Fournel-Fleury C, 2010. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary pathology 47, 414-433. Reif JS, Lower KS,Ogilvie GK, 1995. Residential exposure to magnetic fields and the risk of canine lymphoma. American Journal of Epidemiology 141, 352-359. Sheu JR, Fong TH, Liu CM, Shen MY, Chen TL, Chang Y, Lu MS, Hsiao G, 2004. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. British Journal of Pharmacology 143, 193-201. Simon D, Moreno SN, Hirschberger J, Moritz A, Kohn B, Neumann S, Jurina K, Scharvogel S, Schwedes C, Reinacher M, Beyerbach M, Nolte I, 2008. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. Journal of American Veterinary Medicne Association 232, 879-885. Smith LMS, Capper SJ, 1999. Determination of species cross-reactivity using MMP-2 Activity Assay and correlation with ELISA and gelatin zymography. Life Science News, Amersham Bioscience 3, 1-3. Stein R, Balkman C, Chen S, Rassnick K, Mcentee M, Page R, Goldenberg DM, 2011. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leukemia and Lymphoma 52, 273-284. Timothy MF, 2011. Canine malignant lymphoma: introduction. In: Cynthia MK (Ed.), The merck veterinary manual, 9th ed, online version. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., NJ, USA. Troeberg L, Nagase H, 2005. Zymography of metalloproteinases. In: Coligan JE, Dunn BM, Speicher DW, Wingfield PT (Ed), Current protocols in protein science, online edition. Wiley, NY, USA, section 21.15. Vail DM, MacEwen EG, 2000. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 18, 781-792. Vail DM, Michels GM, Khanna C, Selting KA, London CA, 2009. Response evaluation criteria for peripheral nodal lymphoma in dogs (v 1.0) - a Veterinary Cooperative Oncology Group (VCOG) consensus document. Veterinary and Comparative Oncology 8, 28-37. Valli VE, 2007. The evolution of classification systems for hematopoietic neoplasms. In: Valli VE (Ed.), Veterinary Comparative Hematopathology. Blackwell, Iowa, USA, 3-7. Vezzali E, Parodi AL, Marcato PS, Bettini G, 2010. Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO. Veterinary and Comparative Oncology 8, 38-49. Yang YP, 2011. Prognostic variables, and clonality and phenotyping by polymerase chain reacton and immunohistochemical methods in canine lymphomas. Master's thesis of Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, 23-24, 26. Zahm SH, Blair A, 1992. Pesticides and non-Hodgkin's lymphoma. Cancer Research 52, 5485-5488. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G, Ye YK, Liang YX, Qin WJ, Zhang Z, Zeng GH, Chen ZN, 2008. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant Prognostic factors in human prostate cancer. Oncology 75, 230-236.
摘要: 基質金屬蛋白酵素2及9(MMP-2和MMP-9)在人類的實質固態瘤(solid tumor)中被認為會影響腫瘤細胞的移動、侵犯、轉移和血管新生作用。然而由於明膠酶(gelatinase)相關因子的複雜度,淋巴瘤亞型的多樣性以及較少犬隻相關研究,使明膠酶在犬隻預後評估的價值上仍不明確。因此,此實驗著重在釐清明膠酶和犬隻淋巴瘤間的關係。 在化療前和化療後的復診時收集罹患淋巴瘤犬隻的血清樣本,用明膠酶圖譜分析(gelatin zymography)偵測基質金屬蛋白酵素2及9的濃度。結果顯示,基質金屬蛋白酵素9的濃度在罹患淋巴瘤的犬隻中上升,且在達到完全消退的治療後下降。在基質金屬蛋白酵素2方面,健康對照組、罹患淋巴瘤組和治療中的濃度之間相比都沒有差異。且基質金屬蛋白酵素2及9的濃度在T細胞淋巴瘤比預後較佳的B細胞淋巴瘤高。 此實驗提出基質金屬蛋白酵素9的濃度可以做為犬隻淋巴瘤的預後評估因子,而基質金屬蛋白酵素2則在某些淋巴瘤亞型中扮演較輕的腳色。但因在病患特徵的結果上多變異和一些研究之間的差異,使未來重點放在更多且更大量的樣本研究上。
Gelatinases (MMP-2 and MMP-9) are thought to affect migration, invasion, metastasis and angiogenesis in human solid tumor. However, due to the complex gelatinase-associated factors, diversity of lymphoma subtypes and few researches of canine, the prognostic value of gelatinases in canine lymphoma remains equivocal. Thus this study focuses on clarifying the relation between gelatinases and canine lymphoma. Serum samples of lymphoma-affected dogs were collected before and after chemotherapy at follow-ups, then gelatin zymography was used to detect the levels of MMP-2 and MMP-9. The results suggest that MMP-9 levels increases in lymphoma-affected dogs and decreases after a complete response is achieved; there are no variations of MMP-2 levels between healthy control, lymphoma-affected dogs and levels during treatment. Both MMP-2 and MMP-9 levels are higher in T-cell lymphoma than B-cell lymphoma patients which have better prognosis. This study suggests that MMP-9 could be a prognostic factor of canine lymphoma and MMP-2 may play a minor role in some parts of lymphoma subtypes. But variable results of patient characteristics and some differences between studies make us put an emphasis on more studies and larger sample cases in the future.
URI: http://hdl.handle.net/11455/12913
其他識別: U0005-1306201223255500
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-1306201223255500
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.